The book recognizes that throughout the scientific, medical, and economic communities, new tests incorporating biomarkers are needed to improve the diagnosis of patients suffering from metabolic disorders. The early identification of those at risk of developing obesity will help to place these individuals on the best treatment course as early as possible for improved treatment outcomes. This will also help to cut costs incurred by the healthcare services. For all of this to occur, new research efforts are needed to identify novel biomarkers that can be used to predict the disease in the presymptomatic stage, for disease monitoring and for prediction of treatment response. It is also possible that new drug targets can be identified using these approaches which, in turn, can lead to the development of new treatment approaches. This volume also includes a series of reviews on biomarker discovery and usage in the study of diseases marked by perturbations in metabolism. It will describe the pros and cons of the various approaches and cover the successes and failures in this important research field.

Discusses both positive and negative findings Describes studies of diseases not commonly thought of as having metabolic links or origins Looks at economic aspects of these diseases and the benefits of using biomarkers for the healthcare systems

Autorentext
Dr Paul C. Guest, Ph.D, is a scientific researcher/writer with 35 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and Alzheimer's disease.

Inhalt

1. Insulin Resistance in Schizophrenia.- 2. Biogenesis of the Insulin Secretory Granule in Health and Disease.- 3. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions.- 4. Preclinical Models of Altered Early Life Nutrition and Development of Reproductive Disorders in Female Offspring.- 5. Targeting Mitochondrial Defects to Increase Lngevity in Animal Models of Neurodegenerative Diseases.- 6. Computational Approaches for Identification of Pleiotropic Biomarker Profiles in Psychiatry.- 7. MiRNA Regulation of Glucose and Lipid Metabolism in Relation to Diabetes and Non-Alcoholic Fatty Liver Disease.- 8. Hypercaloric Diet-Induced Obesity and Obesity-Related Metabolic Disorders in Experimental Models.- 9. Metabolic Biomarkers in Nematode C. elegans During Aging.- 10. Circular RNAs as potential biomarkers and therapeutic targets for metabolic diseases.- 11. Deciphering Endothelial Dysfunction in the HIV-Infected Population.- 12. The Role of Inflammationin the Development of GDM and The Use of Markers of Inflammation in GDM Screening.- 13. PFKP Signaling at a Glance: an Emerging Mediator of Cancer Cell Metabolism.- 14. ATAD3A on the Path to Cancer.- 15. Impact of Exercise on Inflammatory Mediators of Metabolic and Vascular Insulin Resistance in Type 2 Diabetes. <p